Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fresenius SE KGaAXSWX:FRE 67 Price-to-Tangible-Book is 8.17 as of Jul. 25, 2026, which is 20% below its 10-year median of 10.27. GuruFocus rates XSWX:FRE with a GF Score™ of 67/100 and a GF Value™ of CHF33.37 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 502 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 81.27% on this metric.
The historical rank and industry rank for Fresenius SE KGaA's Price-to-Tangible-Book or its related term are showing as below:
XSWX:FRE'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.82 Med: 10.27 Max: 16.53
Current: 8.17
During the past 13 years, Fresenius SE KGaA's highest Price to Tangible Book Ratio was 16.53. The lowest was 7.82. And the median was 10.27.
XSWX:FRE's Price-to-Tangible-Book is ranked worse than 81.27% of 502
companies
in the Healthcare Providers & Services industry
Industry Median: 2.65
vs XSWX:FRE: 8.17
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Fresenius SE KGaA Price-to-Tangible-Book Related Terms
Fresenius SE KGaA Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Price-to-Tangible-Book Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Price-to-Tangible-Book vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Fresenius SE KGaA (XSWX:FRE) has a Price-to-Tangible-Book of 8.17 as of Jul. 25, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Fresenius SE KGaA and its competitors. This is 20% below median its historical median of 10.27. Over the past decade, Fresenius SE KGaA's Price-to-Tangible-Book has ranged from 7.82 to 16.53. According to the industry distribution chart, Fresenius SE KGaA ranks #408 out of 502 companies in the Healthcare Providers & Services industry, placing it in the top 81.3%.
Is Fresenius SE KGaA's Price-to-Tangible-Book too high?
Fresenius SE KGaA's current Price-to-Tangible-Book of 8.17 is 20% below median its 10-year median of 10.27. Over the past 10 years, this metric has ranged from a low of 7.82 to a high of 16.53. The Healthcare Providers & Services industry median Price-to-Tangible-Book is 2.65. Fresenius SE KGaA's value of 8.17 is 208.3% above this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #408 out of 502 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Fresenius SE KGaA has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Price-to-Tangible-Book compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #408 out of 502 companies for Price-to-Tangible-Book. This places Fresenius SE KGaA in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.65. Fresenius SE KGaA's value of 8.17 is 208.3% above this benchmark. Historically, Fresenius SE KGaA's own Price-to-Tangible-Book has ranged from 7.82 to 16.53 over the past decade. While the company's 10-year median is 10.27 vs. the industry median of 2.65, Fresenius SE KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Healthcare Providers & Services company?
The median Price-to-Tangible-Book among Healthcare Providers & Services companies is 2.65, based on 502 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current Price-to-Tangible-Book of 8.17 is 208.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median Price-to-Tangible-Book is 2.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Price-to-Tangible-Book is 8.17, which is 20% below median its own 10-year median of 10.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF33.37, compared to a current price of CHF39.86 — trading 19.4% above its estimated fair value. The current Price-to-Tangible-Book is 8.17, which is 20% below median its 10-year median of 10.27 and 208.3% above the Healthcare Providers & Services industry median of 2.65. Fresenius SE KGaA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Price-to-Tangible-Book is 8.17 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF39.86 is trading 19.4% above its estimated GF Value™ of CHF33.37.
GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.
Key valuation signals for XSWX:FRE:
Price-to-Tangible-Book: 8.17 (20% below median its 10-year median of 10.27)
GF Value™: CHF33.37 vs. price of CHF39.86 (19.4% above fair value)
Industry Position: 208.3% above the Healthcare Providers & Services median (#408 of 502)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
67GF Score
Get the complete analysis for XSWX:FRE
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
